Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. - Wikidata - wikimedia - TriplyDB

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

http://www.wikidata.org/entity/Q34568130

about

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response Clopidogrel "resistance": where are we now?Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke.Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Ac Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes.Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention Impact of genetic polymorphisms on clinical response to antithrombotics.Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome.The genetics of antiplatelet drug resistance.Clopidogrel resistance: pharmacokinetic or pharmacogenetic?Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.Proton pump inhibitor and clopidogrel interaction: fact or fiction?Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?Genetic causes of clopidogrel nonresponsiveness: which ones really count?Factors associated with clopidogrel nonresponsiveness.Nonresponders to clopidogrel: pharmacokinetics and interactions involved.Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.Antiplatelet drug interactions.Clopidogrel pharmacogenetics: metabolism and drug interactions.The pharmacogenetics of antiplatelet agents: towards personalized therapy?The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?Genetic and non-genetic factors affecting the response to clopidogrel therapy.Metabolic differences of current thienopyridine antiplatelet agents.CYP3A5 polymorphism, amlodipine and hypertension.Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.Pharmacogenomics of oral antiplatelet drugs.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

P2860

Q26775125-4A0C267B-F88F-4AF7-B74B-816655CD45F4 Q26801867-CE757E17-33D2-47FB-A140-22C6A9A45D60 Q26852535-12161970-0F8E-4800-9012-A460E6E6787C Q28218540-A1C71D8D-1F2B-4FCD-B539-5A8551EB8968 Q33776115-BDF0B36F-84E9-4E8E-BE1D-32C6A51E54F2 Q33903933-CF7A496B-8D4B-4F98-B339-D21119AB7659 Q34212563-B1F3E437-4171-43CA-8E1E-57DEEF2435DD Q34339780-62CE4BAD-5AB2-408C-BA36-CEA7F38534BF Q35208684-7C6DFD77-7907-4478-A780-EDF9181521F6 Q35951677-68B49C80-086E-4F69-9F5C-7650BA16C98C Q36036395-30E559BB-21A5-453F-919A-5A45CAD5E750 Q36062323-A334D09F-9F29-4960-9DD2-1B6F07CDDABC Q36105504-B5A89930-FF2F-4605-98F5-7266D044F2E9 Q36334515-3EBD2972-D2B1-4CFE-8D37-78E1B14C47CB Q36441477-95834845-251E-4846-889C-318238BDE483 Q37027004-111D9BF2-CE42-4642-A77A-647109C9F394 Q37311337-9C99AE9F-FEA7-44AD-8567-5B6050D5ECD3 Q37344920-AE77D4B4-5817-43F5-8E83-76A7F1BCFFC2 Q37402214-AFA20C2B-C67B-4C76-A14A-4318D8A470C2 Q37458916-98F86661-1D75-48CA-B188-8E035EE99CC0 Q37540088-95442ED6-5318-472E-8B41-9991A020DA2B Q37630911-94508E36-9B16-4B83-A8DB-809032209CE2 Q37641606-C90C2066-3B8D-443C-A88C-70D13A06324E Q37651530-C9CDD178-C007-4379-94FF-DB39E291F50F Q37697779-E776E1FE-B769-46D0-80F6-84DAE6A06DA7 Q37709405-9359892A-0D30-49D6-8CA9-2447909EB66A Q37786622-F486131E-E952-4FDA-9257-B307B7724693 Q37806660-5270FAF7-39D9-416D-A5D5-F7C0624AD40E Q37809111-346D9DE5-CC57-4AB0-AC41-82747DD43C62 Q37912178-E70DC762-AB74-451F-ABBD-ED8446CBF327 Q37913976-D3B3F3B2-1555-4C58-B162-CD65B7F5277A Q37923969-19177B36-32C3-4EDB-BB3D-28462AAD5177 Q37924323-4CA11697-B924-4432-BE9F-9737DBB57C46 Q37991382-12F0863D-CCAC-4C3F-B0BC-E80A20B1DFF1 Q38071707-16C1EF5A-8FCF-49D3-8840-98DF0672B466 Q38122295-04804AA4-BF6C-46F2-8A53-851D29740541 Q38148597-5A4774C4-4DF7-4B1A-BD65-A9DCBE15DBBA Q38195628-5458FAC9-8BE8-41BB-91D0-E9F04294C7D1 Q38307535-3EC62107-6956-4B16-8DC1-63361A0D3D41 Q38542096-B12AE929-516F-48D5-BAE6-A4552AD0F2F6

P2860

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

http://www.wikidata.org/entity/Q34568130

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Increased risk of atherothromb ...... n patients taking clopidogrel.

@ast

Increased risk of atherothromb ...... n patients taking clopidogrel.

@en

Increased risk of atherothromb ...... n patients taking clopidogrel.

@nl

type

label

Increased risk of atherothromb ...... n patients taking clopidogrel.

@ast

Increased risk of atherothromb ...... n patients taking clopidogrel.

@en

Increased risk of atherothromb ...... n patients taking clopidogrel.

@nl

prefLabel

Increased risk of atherothromb ...... n patients taking clopidogrel.

@ast

Increased risk of atherothromb ...... n patients taking clopidogrel.

@en

Increased risk of atherothromb ...... n patients taking clopidogrel.

@nl

P1433

Q34568130-473B4407-7512-4A4F-880B-EFF747384897

P1476

Q34568130-FC12B5A9-C3E6-4148-8063-BA3A7F89FF17

P2093

Q34568130-135F91E6-44B5-4CF1-8636-6C821FFBF600

Q34568130-1E84FD75-FC33-4B6C-A369-F57E8313096A

Q34568130-3031BD32-AF45-4E9E-9D9A-0B00511F5055

Q34568130-3D287FEE-A94C-4628-94B7-B0BDB134A135

Q34568130-53740FB8-446B-4391-8B26-03194170D2FC

Q34568130-8EDA9520-16FC-4FF6-9840-46DE96AECB84

Q34568130-923A4D8A-E793-48CA-98D6-23738354A8AB

Q34568130-BF70695D-948D-4590-90E0-3A0E0E45D4DB

Q34568130-CBD3805E-05F5-48DE-8DAA-FA5C30CAB31D

Q34568130-E890434D-7D55-42E8-8B89-9E16B83A8E44

P2860

Q34568130-0F73DC80-11D1-4352-826D-07F5FEF22FDF

Q34568130-1F07CA14-BB2A-4D50-951F-DE7B0F28D727

Q34568130-292B2A51-92EE-4862-B810-6D357B2A912C

Q34568130-424657E1-E23A-46AA-9276-2C74AFC59B6D

Q34568130-4FDB8725-9E4B-47B3-B8BE-68C9C011FCE7

Q34568130-522DECDA-9BA2-4B4C-BA61-B9DEDCDDB903

Q34568130-5B8413AA-CC0A-4919-BB43-93B8C34CBD2E

Q34568130-67F8A310-139A-4E5A-9A5A-676C63A75451

Q34568130-6BE97716-0952-443D-9916-5AB707BF8681

Q34568130-6BE9C2FF-DAF5-4F2E-8DF4-ECEBC4DF4DF7

P304

Q34568130-41E211C6-2EE6-49F7-9EBA-496D63D0D87B

P31

Q34568130-2FD3B58E-7E32-44B5-828B-B8AFA468C8B2

P356

Q34568130-B2391CD5-CD56-47F9-9006-3CF9385803CB

P407

Q34568130-4ECF2A8E-8BF4-408F-80A7-0FD2D9128F16

P433

Q34568130-4F24F994-F932-4513-96DC-3B9A2D63B68E

P478

Q34568130-CDE8F49E-BAE5-4108-BAF8-DC4B494C1F3E

P577

Q34568130-DA7909D0-3870-4C9F-8E37-9898269DDA73

P5875

Q34568130-80DDB2E7-84A6-40C7-A9FC-1F836E4AC074

P698

Q34568130-495A2603-8E9A-49B7-BBF8-A1BEE6C36383

P921

Q34568130-A1576716-C41E-4761-B7EA-C79C9F32A452

Q34568130-CC2AE037-D56F-4E49-AD1E-45915BA032C7

P932

Q34568130-B34B58C4-BF21-43E1-B41F-4166F12D72CD

P356

P1433

Canadian Medical Association Journal

P1476

Increased risk of atherothromb ...... n patients taking clopidogrel.

@en

P2093

Bon-Kwon Koo

http://www.w3.org/2001/XMLSchema#string

Dae-Won Sohn

http://www.w3.org/2001/XMLSchema#string

Dong-Soon Lee

http://www.w3.org/2001/XMLSchema#string

Hyo-Soo Kim

http://www.w3.org/2001/XMLSchema#string

In-Jin Jang

http://www.w3.org/2001/XMLSchema#string

Joo-Youn Cho

http://www.w3.org/2001/XMLSchema#string

Jung-Won Suh

http://www.w3.org/2001/XMLSchema#string

Kyung-Woo Park

http://www.w3.org/2001/XMLSchema#string

Myoung-Mook Lee

http://www.w3.org/2001/XMLSchema#string

Shu-Ying Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A simple salting out procedure for extracting DNA from human nucleated cells

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

The role of ADP receptors in platelet function

Ticlopidine and clopidogrel.

The human CYP3A subfamily: practical considerations.

P304

1715-1722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.060664

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7027928

http://www.w3.org/2001/XMLSchema#string

P698

16754899

http://www.w3.org/2001/XMLSchema#string

P921

P932

1471813

http://www.w3.org/2001/XMLSchema#string